Literature DB >> 20149693

Treatment and long term outcome in West syndrome: the clinical reality. A multicentre follow up study.

Lieven Lagae1, Helène Verhelst, Berten Ceulemans, Linda De Meirleir, Marie-Cécile Nassogne, Valerie De Borchgrave, Marc D'Hooghe, Martine Foulon, Patrick Van Bogaert.   

Abstract

We systematically reviewed the files of 51 infants presenting with infantile spasms and hypsarrhythmia in order to study the initial treatment strategies and the long term outcome. 80% of the infants were classified as symptomatic. In the nine participating centres, different treatment protocols were used, but the large majority of the children received vigabatrin as first line treatment. Second line options included hormonal treatment, topiramate and valproate. The time to reach cessation of infantile spasms was significantly shorter in the cryptogenic group than in the symptomatic group (50% at 13 days versus 66 days respectively) and was irrespective of the treatment used. The late follow up data (>2 years) showed that 60% of the children had epilepsy and that 75% of the children had a delay in their psychomotor development. Again, outcome in the cryptogenic group was better than in the symptomatic group, but also in the cryptogenic group, 50% of the children had a clear developmental delay, even if spasms were controlled early in the course of the disease. Our retrospective study illustrates that not only the underlying brain dysfunction is the major determinant for later outcome in infantile spasms (symptomatic group) but also even a short period of infantile spasms can be responsible for later developmental delay (cryptogenic group). (c) 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20149693     DOI: 10.1016/j.seizure.2010.01.008

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  25 in total

1.  West syndrome caused by homozygous variant in the evolutionary conserved gene encoding the mitochondrial elongation factor GUF1.

Authors:  Ali Abdullah Alfaiz; Verena Müller; Nadia Boutry-Kryza; Dorothée Ville; Nicolas Guex; Julitta de Bellescize; Clotilde Rivier; Audrey Labalme; Vincent des Portes; Patrick Edery; Marianne Till; Ioannis Xenarios; Damien Sanlaville; Johannes M Herrmann; Gaétan Lesca; Alexandre Reymond
Journal:  Eur J Hum Genet       Date:  2015-10-21       Impact factor: 4.246

Review 2.  Recent advances in the pharmacotherapy of infantile spasms.

Authors:  Raili Riikonen
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 3.  Genetic and biologic classification of infantile spasms.

Authors:  Alex R Paciorkowski; Liu Lin Thio; William B Dobyns
Journal:  Pediatr Neurol       Date:  2011-12       Impact factor: 3.372

4.  Diagnosis delay in West syndrome: misdiagnosis and consequences.

Authors:  Stéphane Auvin; Adam L Hartman; Béatrice Desnous; Anne-Christine Moreau; Corinne Alberti; Catherine Delanoe; Alfonso Romano; Gaetano Terrone; Eric H Kossoff; Ennio Del Giudice; Luigi Titomanlio
Journal:  Eur J Pediatr       Date:  2012-08-15       Impact factor: 3.183

Review 5.  Infantile Spasms-Have We Made Progress?

Authors:  Sarah Aminoff Kelley; Kelly G Knupp
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-19       Impact factor: 5.081

6.  Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort.

Authors:  Kelly G Knupp; Erin Leister; Jason Coryell; Katherine C Nickels; Nicole Ryan; Elizabeth Juarez-Colunga; William D Gaillard; John R Mytinger; Anne T Berg; John Millichap; Douglas R Nordli; Sucheta Joshi; Renée A Shellhaas; Tobias Loddenkemper; Dennis Dlugos; Elaine Wirrell; Joseph Sullivan; Adam L Hartman; Eric H Kossoff; Zachary M Grinspan; Lorie Hamikawa
Journal:  Epilepsia       Date:  2016-09-12       Impact factor: 5.864

Review 7.  Modeling epileptic spasms during infancy: Are we heading for the treatment yet?

Authors:  Libor Velíšek; Jana Velíšková
Journal:  Pharmacol Ther       Date:  2020-05-15       Impact factor: 12.310

8.  Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions.

Authors:  Ozlem Akman; Stephen W Briggs; Wenzhu B Mowrey; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Epilepsia       Date:  2021-07-02       Impact factor: 6.740

9.  Randomised clinical efficacy trial of topiramate and nitrazepam in treatment of infantile spasms.

Authors:  Razieh Fallah; Fahimah Salor; Sedighah Akhavan Karbasi; Hadi Motaghipisheh
Journal:  Iran J Child Neurol       Date:  2014

10.  Infantile spasms: A prognostic evaluation.

Authors:  Mary Iype; Geetha Saradakutty; Puthuvathra Abdul Mohammed Kunju; Devi Mohan; Muttathu Krishnapanicker Chandrasekharan Nair; Babu George; Shahanaz M Ahamed
Journal:  Ann Indian Acad Neurol       Date:  2016 Apr-Jun       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.